RFXANK and obesity due to melanocortin 4 receptor deficiency: However, RFXANK has not been associated with obesity or T2D in previous studies, though MHCII has been found to play a role in obesity [51], and our own prior studies have identified pathways related to inflammation and immunity as common themes in individuals at risk for T2D [52].